Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ipragliflozin/sitagliptin - Astellas Pharma/MSD KK

Next Previous
Drug Profile

Ipragliflozin/sitagliptin - Astellas Pharma/MSD KK

Alternative Names: Ipragliflozin L-proline/sitagliptin; MK 0431J; Sitagliptin phosphate hydrate/ipragliflozin L-Proline; Sitagliptin/ipragliflozin; Sitagliptin/ipragliflozin L-proline; SUJANU

Latest Information Update: 30 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astellas Pharma; MSD KK
  • Developer Astellas Pharma; Kotobuki Pharmaceutical; MSD KK
  • Class Antihyperglycaemics; Glucosides; Pyrazines; Small molecules; Thiophenes; Triazoles
  • Mechanism of Action Dipeptidyl peptidase 4 inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 22 May 2018 Launched for Type-2 diabetes mellitus in Japan (PO) - First Global Launch
  • 23 Mar 2018 Registered for Type-2 diabetes mellitus in Japan (PO)
  • 26 May 2017 Chemical structure information added
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top